Are Market Conditions Setting Up A Biopharma M&A Wave?
EY Beyond Borders Report Predicts An Uptake Is Coming
Executive Summary
A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.
You may also be interested in...
BIO 2022 Notebook: Staying Afloat In Rough Waters
News and views from day two of the BIO annual meeting include reflections on the ups and downs of the financing environment, Cerevance CEO Craig Thomson on the challenges of raising VC funds right now, and Bayer business development exec Marianne de Backer explains that it's not a good strategy to buy things just because they are on sale.
Volatility And Valuations Among Factors Weighing On Pharma Deal Making
Market volatility, persistently high valuations, inflation and interest rates are among the issues sidetracking broader M&A, experts say.
Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.